Bacil Pharma Limited has incorporated a wholly owned subsidiary named Bacil Research & Development Private Limited. The company disclosed the formation in a filing with BSE Limited on July 28, 2026, citing Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The move establishes a dedicated legal entity for research and development activities within the group structure.

The incorporation was formalized by the Ministry of Corporate Affairs on July 28, 2026. Bacil Research & Development Private Limited is registered as a company limited by shares under the Companies Act, 2013. The Central Registration Centre issued the Certificate of Incorporation from Manesar, confirming the legal status of the new entity.

Subsidiary Details

The new subsidiary operates under the following corporate identifiers and details:

The registered office for Bacil Research & Development Private Limited is located at G2 Samarpan Complex, Link Road Opp. Satam Wadi, Sahar P & T Colony, Mumbai. This address is distinct from the parent company's registered office at G2 & G3 Samarpan Complex, Next to Mirador Hotel, Chakala, Andheri East, Mumbai.

Regulatory Disclosure

The disclosure was signed by Ms. Chaitali Kalpataru Shah, Director & CFO of Bacil Pharma Limited. The filing serves as an intimation to the stock exchange regarding the change in the corporate structure. The parent company previously issued a letter dated July 7, 2026, preceding this final confirmation of incorporation.

Structural Significance

The establishment of a separate R&D subsidiary indicates a structural segmentation of Bacil Pharma Limited's operations. By creating a distinct legal entity for research functions, the group aims to isolate development costs or manage intellectual property assets separately from its core manufacturing and sales operations. The immediate financial impact is not detailed in the filing, but the creation of the entity marks a formal step in organizing the company's innovation pipeline.

bacil pharma has approved a proposal to raise funds by way of a rights issue of equity shares for an aggregate amount of up to ₹50 Cr. The decision was taken during a board meeting held on July 9, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company intends to utilise the capital to bolster its financial resources, subject to statutory and regulatory approvals.

The board approved increasing the authorised share capital by ₹45 Cr through the addition of 4,50,00,000 equity shares of ₹10 each. Following this increase, the total authorised capital will stand at ₹65 Cr. This move requires the consequent alteration of the capital clause of the Memorandum of Association and is subject to shareholder approval in the upcoming general meeting.

To facilitate the rights issue, the board appointed M/s Purva Sharegistry (India) Private Limited as the registrar and Axis Bank Limited as the banker to the issue. Acuite Ratings & Research Limited was appointed as the monitoring agency in accordance with SEBI ICDR Regulations. A rights issue committee was formed, comprising Chaitali Kalpataru Shah as Chairman and Vivek Mukesh Yadav and Omprakash Pyarelal Sonar as members.

The board accepted the resignations of Mr. Dinesh Chander Notiyal and Ms. Avani Savjibhai Godhaniya as independent directors, effective July 9, 2026. Both directors cited pre-occupation in other assignments and an inability to devote sufficient time to the company's affairs as reasons for their departure. The trading window for dealing in the company's securities will remain closed for all designated persons and their immediate relatives until 48 hours after the declaration of the board meeting outcome.